Back to discover
Disease

Eye Infections, Bacterial

Late-stage therapeutic developmentEmerging research
MeSHEye Infections, Bacterial
2
Publications
4
Clinical trials
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Delafloxacinapproved

Approval — Quofenix is indicated for the treatment of the following infections in adults: acute bac… (2019)

Dalbavancin hydrochlorideapproved

Approval — Xydalba is indicated for the treatment of acute bacterial skin and skin structure infecti… (2015)

Tedizolidapproved

Approval — Sivextro tablets are indicated for the treatment of acute bacterial skin and skin structu… (2015)

Filgrastimapproved

Approval — Filgrastim is indicated for the reduction in the duration of neutropenia and the incidenc… (2010)

Clinical trials

2 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
4
All trials
0
Active
1
Late-stage
3
Completed
Late-stage studies

Steroids for Corneal Ulcers Trial

Phase 4 · Completed · Thomas M. Lietman

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2019emaApproval — Delafloxacin· Quofenix is indicated for the treatment of the following infections in adults: acute bacterial skin and skin structure infections (ABSSSI), community-acquired pneumonia (CAP), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4.4 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents. source ↗
2015emaApproval — Tedizolid· Sivextro tablets are indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults, adolescents and children weighing at least 35 kg.Consideration should be given to official guidance on the appropriate use of antibacterial agents. Sivextro powder for concentrate for solution for infusion is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) from birth. Consideration should be given to official guidance on the appropriate use of antibacterial agents. source ↗
2015emaApproval — Dalbavancin hydrochloride· Xydalba is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients from birth (see sections 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents. source ↗
2010emaApproval — Filgrastim· Filgrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy. Filgrastim is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs). In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ?0.5 x 109/l and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events. Filgrastim is indicated for the treatment of persistent neutropenia (ANC ?1.0 x 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20072023
Major themes6
  • Antibiotic Prophylaxis1
  • Corneal Ulcer1
  • Eye Infections, Bacterial1
  • Keratitis1
  • Levofloxacin1
  • Phacoemulsification1
Leading journals2
  • Indian journal of ophthalmology1
  • Journal of cataract and refractive surgery1
Leading researchers7
  • Ambastha A1
  • Arya LK1
  • Kumari A1
  • Kumari N1
  • Kusumesh R1
  • Mohan N1
  • Sinha BP1
Affiliations (unnormalised)2
  • Department of Microbiology Indira Gandhi Institute of Medical Sciences1
  • Regional Institute of Ophthalmology1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Infections in the inner or external eye caused by microorganisms belonging to several families of bacteria. Some of the more common genera found are Haemophilus, Neisseria, Staphylococcus, Streptococcus, and Chlamydia.

Identifiers
MeSHEye Infections, Bacterial
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.